Clinical trial
Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS…
NCT00002414 · Centaur Pharmaceuticals, Industry · Unknown status
Key facts
| NCT number | NCT00002414 |
|---|---|
| Title | Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia |
| Official title | Randomized, Double-Blind, Parallel Group, Placebo Controlled, Tolerability, Safety and Pilot Efficacy Study of CPI-1189 in HIV Infected Individuals With Cognitive and Motor Impairment |
| Lead sponsor | Centaur Pharmaceuticals, Industry |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | CPI-1189 |
| Enrollment | 60 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: